Merck’s Discounted Zocor Has Had “Negligible Impact,” Teva Says

The generic manufacturer has captured over 70% of the generic market for its four strengths of simvastatin.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet